The association between coeliac disease and cardiovascular disease

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 6, 2008, Pages 514-519

  Wei, L ^a   Spiers, E ^b   Reynolds, N ^b   Walsh, S ^b   Fahey, T ^c   MacDonald, T M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b NINEWELLS HOSPITAL   (United Kingdom)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; ENDOMYSIUM ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELIAC DISEASE; CHILD; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; INTESTINE BIOPSY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CELIAC DISEASE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; SCOTLAND;

EID: 39749154376     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03594.x     Document Type: Article

References (19)

1. Dube C, Rostom A, Sy R, et al. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology 2005 128: S57 67.
2. Lim PO, Tzemos N, Farquharson CA, et al. Reversible hypertension following coeliac disease treatment: the role of moderate hyperhomocysteinaemia and vascular endothelial dysfunction. J Hum Hypertens 2002 16: 411 5.
3. Forman JP, Rimm E, Stampfer M, et al. Folate intake and the risk of incident hypertension in US women. JAMA 2005 293: 320 9.
4. West J, Logan RF, Hill PG, et al. Seroprevalence, correlates and characteristics of undetected coeliac disease in England. Gut 2003 52: 960 5.
5. Thomason K, West J, Logan RF, et al. Fracture experience of patients with coeliac disease: a population based survey. Gut 2003 52: 518 22.
6. Prati D, Bardella MT, Peracchi M, et al. North Italy Transplant Programme Working Group (NITp). High frequency of anti-endomysial reactivity in candidates to heart transplant. Dig Liver Dis 2002 34: 39 43.
7. Peters U, Askling J, Gridley G, et al. Causes of death in patients with celiac disease in a population-based Swedish cohort. Arch Intern Med 2003 163: 1566 72.
8. West J, Logan RF, Card TR, et al. Risk of vascular disease in adults with diagnosed coeliac disease: a population-based study. Aliment Pharmacol Ther 2004 20: 73 9.
9. Goodwin FC, Beattie RM, Millar J, et al. Celiac disease and childhood stroke. Pediatr Neurol 2004 31: 139 42.
10. Bahloul M, Chaari A, Khlaf-Bouaziz N, et al. Celiac disease, cerebral venous thrombosis and protein S deficiency, a fortuitous association? J Mal Vasc 2005 30: 228 30.
11. Wei L, Parkinson J, MacDonald TM. The Tayside Medicines Monitoring Unit (MEMO). In: Strom BL, ed. Pharmacoepidemiology, 4th edn. Chichester: John Wiley and Sons, 2005: 323 36.
12. Data Quality Assurance. http://www.isdscotland.org/isd/4943.html (accessed on 3rd January 2008)
13. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006 333: 15 (Epub 21 June 2006).
14. Bonaa KH, Njolstad I, Ueland PM, et al. NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006 354: 1578 88.
15. Lonn E, Yusuf S, Arnold MJ, et al. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006 354: 1567 77.
16. Wald DS, Wald NJ, Morris JK, et al. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 2006 333: 1114 7.
17. James MW, Scott BB. Endomysial antibody in the diagnosis and management of coeliac disease. Postgrad Med J 2000 76: 466 8.
18. Turner R. Scottish Health Survey 1995, Vol. 1, Chapter 4: Smoking. Edinburgh: The Stationary Office, 1997: 140 1.
19. MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997 315: 1333 7.